by Plus Therapeutics | Nov 28, 2024 | Uncategorized
Thankful for the Oncology Community: Celebrating Patients, Caregivers, and Medical Advancements As we take time to reflect on the progress in the field of oncology, Plus Therapeutics extends our deepest gratitude to the patients, caregivers, and the dedicated medical...
by Plus Therapeutics | Nov 15, 2024 | Uncategorized
ICYMI: Watch the Plus Therapeutics Q3 2024 Conference Call Webcast Replay Catch up on the latest financial results and updates from Plus Therapeutics! If you missed yesterday’s conference call, don’t worry – you can still access the webcast replay to hear...
by Plus Therapeutics | Nov 9, 2024 | Uncategorized
Join Plus Therapeutics at the Upcoming 5K Event in New York! Meet Our Patient Advocacy Team Speaking about ReSPECT-GBM and Recurrent Glioblastoma Don’t miss the chance to visit the Plus Therapeutics booth at the ABTA NYC community 5K next week in New York! We’re...
by Plus Therapeutics | Nov 6, 2024 | Uncategorized
BREAKING NEWS: Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership Partnership will expand Plus’ capability to meet late-stage clinical and commercial forecasts for Rhenium (186Re) Obisbemeda and reinforce supply chain redundancy Press...
by Plus Therapeutics | Oct 30, 2024 | Uncategorized
Come join us at the upcoming @the_abta 5K run in New York City! It’s not too late to register as we join together in the fight against brain cancer. Plus Therapeutics is proud to be a sponsor and will have a booth on-site to provide education about our clinical...
by Plus Therapeutics | Sep 30, 2024 | Uncategorized
Reminder to come by Plus Therapeutics at the @CNS_update 2024 Annual Meeting at Booth #2038 Plus Therapeutics is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the...
Recent Comments